Enfuvirtide |
| Catalog No.GC11162 |
HIV fusion inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 159519-65-0
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protocol
Animal experiment: | For infection with the resistant HIV strains, 7-day-cultured macrophages (105 cells/well in 96-well plates) are incubated with or without IFN-λ1, λ2, or λ3 (100 ng/mL each) and/or anti-HIV drugs: Azidothymidine (AZT) 10 pM; Efavirenz 100 pM; Indinavir 10-3 pM, and Enfuvirtide 10 nM for 24 h. Cells are then infected with different strains of HIV (6 ng p24/well) for 2 h. After washed three times with plain DMEM, cells are cultured with fresh 10% DMEM containing IFN-λs and/or antiretroviral drugs. For HIV Bal infection, culture supernatant is harvested at day 8 post infection for RT and p24 assays. Infected and untreated cells served as controls. HIV Gag gene expression in infected cells is also examined at day 8 post infection. For anti-HIV drug-resistant virus (A012 G691-6 or TC49) infection, culture supernatant is harvested for HIV p24 protein by ELISA at days 3, 5, 7, and 10 postinfection. The cell cultures are replaced with the fresh media supplemented with IFN-λ1, λ2, or λ3 and/or the antiretrovirals every 2–3 days. The culture supernatant collected at day 10 postinfection is also subjected to RT assay[3]. |
References: [1]. Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep. 2017 Mar 30;7:45647. | |
| Cas No. | 159519-65-0 | SDF | |
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C)([H])CC1=CC=C(O)C=C1)([H])[C@@](O)([H])C)([H])CO)([H])CC(C)C)([H])[C@@](CC)([H])C)([H])CC2=CN=CN2)([H])CO)([H])CC(C)C)([H])/C(O) | ||
| Formula | C204H301N51O64 | M.Wt | 4491.88 |
| Solubility | ≥ 149.7mg/mL in DMSO with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2226 mL | 1.1131 mL | 2.2262 mL |
| 5 mM | 0.0445 mL | 0.2226 mL | 0.4452 mL |
| 10 mM | 0.0223 mL | 0.1113 mL | 0.2226 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GC13398 RG 108
- GC10844 SCS
- GC44419 N-methyl Paroxetine
- GC16274 DL-threo-2-methylisocitrate sodium
- GC10515 Tertiapin-Q
- GC45319 1-Stearoyl-3-Arachidoyl-rac-glycerol
- GC13271 BEZ235 Tosylate
- GC19506 NITD008
- GN10088 Isoliquiritigenin
- GC41955 17-DMAG
- GC34037 Etofylline
- GN10311 N－Methylcytisine
- GC32744 NMDI14
- GC40026 cis-10-Heptadecenoic Acid methyl ester
- GC60794 Drinidene
- GC37610 Scyllo-Inositol
Reviews
Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *